114 related articles for article (PubMed ID: 17986862)
1. Novel C5a agonist-based dendritic cell vaccine in a murine model of melanoma.
Floreani AA; Gunselman SJ; Heires AJ; Hauke RJ; Tarantolo S; Jackson JD
Cell Cycle; 2007 Nov; 6(22):2835-9. PubMed ID: 17986862
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
3. Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture.
Eggert AO; Becker JC; Ammon M; McLellan AD; Renner G; Merkel A; Bröcker EB; Kämpgen E
Eur J Immunol; 2002 Jan; 32(1):122-7. PubMed ID: 11754352
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma.
Shibagaki N; Udey MC
Eur J Immunol; 2003 Apr; 33(4):850-60. PubMed ID: 12672050
[TBL] [Abstract][Full Text] [Related]
5. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration.
Eggert AA; Schreurs MW; Boerman OC; Oyen WJ; de Boer AJ; Punt CJ; Figdor CG; Adema GJ
Cancer Res; 1999 Jul; 59(14):3340-5. PubMed ID: 10416590
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
8. [Inhibiting effect of IL-10 in tumor microenvironment on anti-tumor activity of SOCS1-silenced DC vaccine].
Wang Z; You H; Song S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Apr; 29(4):379-83. PubMed ID: 23643168
[TBL] [Abstract][Full Text] [Related]
9. A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model.
McWilliams JA; McGurran SM; Dow SW; Slansky JE; Kedl RM
J Immunol; 2006 Jul; 177(1):155-61. PubMed ID: 16785510
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effect of dendritic cells loaded with a fusion mRNA encoding tyrosinase-related protein 2 and enhanced green fluorescence protein on B16 melanoma.
Fukui M; Nakano-Hashimoto T; Okano K; Maruta Y; Suehiro Y; Hamanaka Y; Yamashita H; Imai K; Kawano MM; Hinoda Y
Tumour Biol; 2004; 25(5-6):252-7. PubMed ID: 15627888
[TBL] [Abstract][Full Text] [Related]
11. Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination.
Steitz J; Tormo D; Schweichel D; Tüting T
Cancer Gene Ther; 2006 Mar; 13(3):318-25. PubMed ID: 16151477
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
Aravindaram K; Wang PH; Yin SY; Yang NS
Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
[TBL] [Abstract][Full Text] [Related]
13. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
14. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
15. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice.
DeMatos P; Abdel-Wahab Z; Vervaert C; Hester D; Seigler H
J Surg Oncol; 1998 Jun; 68(2):79-91. PubMed ID: 9624036
[TBL] [Abstract][Full Text] [Related]
16. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors.
Iwata-Kajihara T; Sumimoto H; Kawamura N; Ueda R; Takahashi T; Mizuguchi H; Miyagishi M; Takeda K; Kawakami Y
J Immunol; 2011 Jul; 187(1):27-36. PubMed ID: 21632716
[TBL] [Abstract][Full Text] [Related]
17. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein.
Shimizu K; Thomas EK; Giedlin M; Mulé JJ
Cancer Res; 2001 Mar; 61(6):2618-24. PubMed ID: 11289139
[TBL] [Abstract][Full Text] [Related]
19. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice.
Mahnke K; Qian Y; Fondel S; Brueck J; Becker C; Enk AH
Cancer Res; 2005 Aug; 65(15):7007-12. PubMed ID: 16061687
[TBL] [Abstract][Full Text] [Related]
20. Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells as antigen source in DC-based vaccination in the B16-F1 murine melanoma model.
Mac Keon S; Bentivegna S; Levy EM; Marks MS; Mantegazza AR; Wainstok R; Mordoh J
Vaccine; 2019 Aug; 37(35):4947-4955. PubMed ID: 31307876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
